Toronto Congenital Cardiac Centre for Adults, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, University of Toronto, 200 Elizabeth Street, Toronto, Ontario, M5G 2C4, Canada.
Biosense Webster, Irvine, USA.
J Interv Card Electrophysiol. 2020 Sep;58(3):299-306. doi: 10.1007/s10840-019-00580-5. Epub 2019 Aug 9.
Mapping and ablation of atrial tachycardia (AT) is commonly performed in lateral tunnel Fontan (LTF) patients, yet there is little information on the need of baffle puncture to access the pulmonary venous atrium (PVA). This study aimed to evaluate the most common chamber location of critical sites for majority of AT in LTF patients.
Consecutive LTF patients underwent catheter-based high-density mapping and ablation of AT from Nov. 2015 to Mar. 2019. Critical sites were identified by a combination of activation and entrainment mapping. Acute procedural success was defined as AT termination with ablation and non-inducibility of any AT. Predictors for ablation failure were evaluated in retrospect.
Fifteen catheter ablation procedures were performed in 9 patients. A total of 15 clinical ATs (mean TCL 369 ± 91 ms) were mapped. The mechanism was macro re-entry in 11 (73%) and micro re-entry in 2. In 11 ATs (73%), 94 ± 5% of tachycardia cycle length (TCL) were mapped inside the tunnel. The commonest site of successful ablation in the tunnel was on the lateral wall (60%). Trans-baffle access was obtained during 5 of 15 procedures (33%). Overall, procedural success was achieved in 9 of 15 procedures (60%). There were no complications. Recurrence of AT was 42% over a follow-up period of 4.3 ± 3.2 years. Faster TCL of 200-300 ms showed a trend towards ablation failure, (OR 17, 95% CI 0.7 to 423, p = 0.08).
Catheter ablation can be performed effectively for ATs in LTF patients usually from inside the tunnel. ATs with critical sites in the PVA are uncommon. This information will help plan ablation in LTF patients without resorting to initial trans-baffle access.
在外侧隧道 Fontan(LTF)患者中,通常会对房性心动过速(AT)进行标测和消融,但对于进入肺静脉心房(PVA)所需的横膈穿刺了解甚少。本研究旨在评估 LTF 患者中大多数 AT 的关键部位最常见的腔室位置。
2015 年 11 月至 2019 年 3 月,连续 LTF 患者接受基于导管的高密度标测和 AT 消融。通过激活和拖带标测相结合来确定关键部位。急性程序成功定义为 AT 终止,消融后无任何 AT 诱发。回顾性评估消融失败的预测因素。
9 例患者共进行了 15 次导管消融手术。共标测到 15 种临床 AT(平均 TCL369±91ms)。机制为 11 例(73%)为大折返,2 例为微折返。在 11 种 AT 中(73%),94±5%的心动过速周长(TCL)在隧道内标测。在隧道内成功消融的最常见部位是侧壁(60%)。在 15 个程序中的 5 个(33%)中获得了横膈穿刺通道。总的来说,15 个程序中有 9 个(60%)获得了程序成功。没有并发症。在 4.3±3.2 年的随访期间,AT 复发率为 42%。200-300ms 较快的 TCL 显示消融失败的趋势(OR17,95%CI0.7 至 423,p=0.08)。
导管消融可有效治疗 LTF 患者的 AT,通常在隧道内进行。PVA 内有关键部位的 AT 并不常见。这些信息将有助于在不进行初始横膈穿刺的情况下为 LTF 患者计划消融。